Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea.

Trial Profile

Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Planned end date changed from 1 Apr 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top